Genmab A/S (CPH: GMAB), a biotechnology company specialising in the creation and development of differentiated antibody therapeutics for the treatment of cancer, announced on Monday the grant by the European Commission (EC) of marketing authorisation for DARZALEX (daratumumab) in combination with bortezomib, thalidomide and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma, who are eligible for autologous stem cell transplant (ASCT).
This EC approval follows a positive opinion issued for DARZALEX by the CHMP of the European Medicines Agency (EMA) in December 2019. In August 2012, Genmab had granted Janssen Biotech Inc (Janssen) an exclusive worldwide license to develop, manufacture and commercialise daratumumab.
Reportedly, this approval was based on the phase III CASSIOPEIA (MMY3006) study sponsored by the French Intergroupe Francophone du Myelome (IFM) in collaboration with the Dutch-Belgian Cooperative Trial Group for Haematology Oncology (HOVON) and Janssen R&D LLC. Data from this study was published in The Lancet and presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study